Skip to content

SIGNPATH PHARMA, INC.: 10-K filed 2013-04-01

What SIGNPATH PHARMA, INC. reported in its annual report filed 2013-04-01 (fiscal FY 2012): 22 published measures, 60 facts as tagged in accession 0001096906-13-000421.

This filing

Form
10-K (annual report)
Filed
2013-04-01
Fiscal period
fiscal FY 2012
Accession
0001096906-13-000421 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All SIGNPATH PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-12-3132,066USD
At 2011-12-3121,833USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-12-31-7,411,543USD
At 2011-12-31-6,365,485USD
At 2010-12-31-4,692,649USD
At 2009-12-31-2,778,636USD
At 2008-12-3198,021USD
At 2007-12-31-297,958USD
At 2006-12-3110,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-1,310,934USD366
2006-05-15 to 2012-12-31-8,711,536USD2423
2011-01-01 to 2011-12-31-2,284,393USD365
2010-01-01 to 2010-12-31-2,119,059USD365
2009-01-01 to 2009-12-31-730,743USD365
2008-01-01 to 2008-12-31-1,695,766USD366
2007-01-01 to 2007-12-31-526,833USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-883,328USD366
2006-05-15 to 2012-12-31-4,326,112USD2423
2011-01-01 to 2011-12-31-1,209,103USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2006-05-15 to 2012-12-315,390USD2423

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-12-31894,826USD366
2006-05-15 to 2012-12-314,363,424USD2423
2011-01-01 to 2011-12-311,180,534USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2006-05-15 to 2012-12-31-5,390USD2423

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-12-31144USD
At 2011-12-311,409USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-12-319,027USD366
2011-01-01 to 2011-12-31221,274USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-1,312,406USD366
2006-05-15 to 2012-12-31-7,744,246USD2423
2011-01-01 to 2011-12-31-2,039,306USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-12-3131,922USD
At 2011-12-3120,424USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-12-317,443,609USD
At 2011-12-316,387,318USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-01-01 to 2012-12-311,312,406USD366
2006-05-15 to 2012-12-317,744,246USD2423
2011-01-01 to 2011-12-312,039,306USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-01-01 to 2012-12-31939,297USD366
2006-05-15 to 2012-12-313,455,931USD2423
2011-01-01 to 2011-12-311,190,841USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-12-3112,837,500shares
At 2011-12-3112,837,500shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-12-311,286,613USD
At 2011-12-311,021,857USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-12-315,390USD
At 2011-12-315,390USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-1,310,934USD366
2006-05-15 to 2012-12-31-8,711,536USD2423
2011-01-01 to 2011-12-31-2,284,393USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-3145,596USD366
2006-05-15 to 2012-12-311,249,639USD2423
2011-01-01 to 2011-12-31155,436USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-01-01 to 2012-12-311,265USD366
2006-05-15 to 2012-12-315,246USD2423
2011-01-01 to 2011-12-311,264USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2012-01-01 to 2012-12-311,471USD366
2006-05-15 to 2012-12-31-967,291USD2423
2011-01-01 to 2011-12-31-245,087USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2006-05-15 to 2012-12-3110,000USD2423

Inspect the source

Entity
SIGNPATH PHARMA, INC. / CIK 0001455694
Captured
SEC response SHA-256
571c6c49907c5089f4ba741647c70ec6289859c58fc4769a714d176dd34fe3b6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001455694.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))